Target Name: MIR21
NCBI ID: G406991
Review Report on MIR21 Target / Biomarker Content of Review Report on MIR21 Target / Biomarker
MIR21
Other Name(s): hsa-miR-21-3p | microRNA 21 | miR-21 | MicroRNA 21 | hsa-miR-21-5p | hsa-mir-21 | miRNA21 | MIRN21

MIR21: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

MIR21 (hsa-miR-21-3p) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

MIR21 is a microRNA (miRNA), a small non-coding RNA molecule that plays a crucial role in gene expression regulation. It is expressed in a variety of tissues and cells and can interact with other molecules to regulate gene expression. One of the key functions of MIR21 is to regulate the expression of target genes that are associated with various diseases, including cancer.

Studies have shown that MIR21 is involved in the regulation of cell cycle progression, apoptosis, and inflammation. It has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the key reasons for the potential drug target status of MIR21 is its role in cancer. Cancer is a leading cause of death worldwide, and there is a high demand for new treatments that can effectively target this deadly disease. MIR21 has been shown to be involved in the regulation of cancer cell growth and has been identified as a potential drug target for cancer treatment.

In addition to its potential as a cancer drug target, MIR21 has also been identified as a potential biomarker for cancer. The ability to detect and measure the expression of MIR21 in cancer cells has led to the development of new diagnostic tests for cancer. This has the potential to improve the accuracy and effectiveness of cancer diagnosis and treatment.

Another promising aspect of MIR21 is its role in neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and are some of the most common causes of dementia and disability. MIR21 has been shown to play a role in the regulation of neurodegenerative disease and has been identified as a potential drug target for these diseases.

MIR21 has also been shown to be involved in the regulation of autoimmune diseases. Autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, are characterized by the immune system attacking the body's own tissues. MIR21 has been shown to play a role in the regulation of autoimmune disease and has been identified as a potential drug target for these diseases.

In conclusion, MIR21 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments. Further research is needed to fully understand the role of MIR21 in disease and to develop effective new treatments.

Protein Name: MicroRNA 21

The "MIR21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059 | MIR3064 | MIR3065 | MIR3074 | MIR3085 | MIR30A | MIR30B | MIR30C1 | MIR30C2 | MIR30D | MIR30E | MIR31 | MIR3115 | MIR3116-1 | MIR3116-2 | MIR3117 | MIR3118-1 | MIR3118-2 | MIR3118-3 | MIR3118-4 | MIR3118-5 | MIR3118-6 | MIR3119-1 | MIR3119-2 | MIR3120 | MIR3121 | MIR3122 | MIR3123 | MIR3124 | MIR3125 | MIR3126 | MIR3127